BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26597083)

  • 1. Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome.
    Xu C; Wang Z; Cui R; He H; Lin X; Sheng Y; Zhang H
    BMC Cancer; 2015 Nov; 15():925. PubMed ID: 26597083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
    Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological correlation between expression of PTHrP receptor and various prognostic factors in breast cancer without axillary lymph node metastasis.
    Suzuki Y; Tokuda Y; Saito Y; Umemura S; Osamura RY
    Tokai J Exp Clin Med; 2005 Jul; 30(2):127-32. PubMed ID: 16146204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
    Hazelbag S; Kenter GG; Gorter A; Fleuren GJ
    Int J Cancer; 2004 Dec; 112(6):1020-8. PubMed ID: 15386352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
    Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
    Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.
    Henderson MA; Danks JA; Slavin JL; Byrnes GB; Choong PF; Spillane JB; Hopper JL; Martin TJ
    Cancer Res; 2006 Feb; 66(4):2250-6. PubMed ID: 16489028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
    Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
    BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of the parathyroid hormone-related protein expression in breast carcinoma.
    Yoshida A; Nakamura Y; Shimizu A; Harada M; Kameda Y; Nagano A; Inaba M; Asaga T
    Breast Cancer; 2000; 7(3):215-20. PubMed ID: 11029801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
    Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
    J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The parathyroid hormone-related protein (PTHrP) gene: use of downstream TATA promotor and PTHrP 1-139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis.
    Bouizar Z; Spyratos F; De vernejoul MC
    J Bone Miner Res; 1999 Mar; 14(3):406-14. PubMed ID: 10027905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cadherin association with clinicopathological features and prognosis in axillary lymph node-positive breast cancer.
    Kong DD; Yang J; Li L; Wang W; Chen YN; Wang SB; Zhou YZ
    Breast Cancer Res Treat; 2015 Feb; 150(1):119-26. PubMed ID: 25677746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin expression predicts early recurrence in early-stage breast cancer.
    Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
    Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
    Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
    J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.